HCT-15 Xenograft Model Service for Colon Cancer

The HCT-15 xenograft model offers a robust preclinical platform for evaluating therapeutic efficacy against colorectal adenocarcinoma, faithfully recapitulating the genetic complexity and aggressive growth patterns characteristic of human colon cancer. At Alfa Cytology, we specialize in delivering validated, reproducible HCT-15 xenograft models tailored to your drug development pipeline---from initial tumor establishment and longitudinal monitoring to comprehensive endpoint histopathological and molecular analyses---ensuring high-quality preclinical data that accelerate your oncology research programs.

Overview of HCT-15 Xenograft Model for Colon Cancer

HCT-15 is a human colorectal adenocarcinoma cell line originally established in the early 1970s from a primary colon tumor of a male patient diagnosed with Dukes' type C disease. Morphologically, these cells present an epithelial-like appearance with adherent monolayer growth and a tendency to form multicellular clusters, reflecting the cellular heterogeneity commonly observed in solid tumors. Genotypically, HCT-15 exhibits a hyperdiploid karyotype (modal number 46, XY) with characteristic chromosomal aberrations including loss of chromosomes 8, 11, and 17, as well as translocation t(8;17)(p23;q21) and inversion inv(11)(p15.3;q13.1). Molecular profiling has identified activating mutations in KRAS alongside loss-of-function alterations affecting the TP53 pathway, conferring an aggressive proliferative phenotype and intrinsic resistance to multiple chemotherapeutic agents including 5-fluorouracil, SN-38 (the active metabolite of irinotecan), and taxanes. These genetic and biological attributes make HCT-15 a representative model for studying oncogenic signaling, chemoresistance mechanisms, and tumor microenvironment interactions in colorectal cancer research.

In vivo, HCT-15 cells demonstrate robust tumorigenicity in immunocompromised murine hosts such as athymic nude mice and NOD-SCID strains, achieving a 100% tumor take rate typically within three weeks post-implantation. The resulting xenografts retain key histopathological features of human colorectal adenocarcinoma, including glandular architecture, high mitotic index, and stromal infiltration patterns. Both subcutaneous and orthotopic transplantation approaches have been validated: subcutaneous models enable straightforward tumor volume monitoring and high-throughput therapeutic screening, while orthotopic implantation into the cecum or colon wall more accurately recapitulates local tumor progression, angiogenesis, and metastatic dissemination. The model has been extensively applied to evaluate cytotoxic agents, targeted biologics, oncolytic virotherapy, and differentiation therapy strategies, providing critical translational insights that bridge in vitro findings and clinical outcomes.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting colorectal adenocarcinoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving colon cancer progression through KRAS and TP53 mutations, and how treatments intersect with chemoresistance mechanisms.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment.

Figure 1. Cell viability and antiproliferative effect of acetylshikonin-treated HCT-15 and LoVo cells. (Lim, Heui Min, et al., 2021)

Cell Line Information: HCT-15

The HCT-15 cell line is a well-established human colorectal adenocarcinoma line with comprehensive molecular characterization. Its hyperdiploid karyotype, KRAS activating mutation, and intrinsic resistance to multiple chemotherapeutic agents make it unique among available colon cancer cell lines and essential for preclinical research targeting chemoresistant colorectal carcinoma.

Our Services

Alfa Cytology provides end-to-end HCT-15 xenograft model services encompassing cell line authentication, in vivo tumor establishment, treatment administration, longitudinal tumor monitoring, and comprehensive endpoint analysis including histopathology, immunohistochemistry, and molecular profiling. Our experienced scientific team ensures rigorous quality control, standardized protocols, and timely data delivery to support your preclinical oncology research and accelerate therapeutic candidate evaluation.

Workflow of HCT-15 Xenograft Model Construction

The construction of HCT-15 xenograft models follows a systematic, quality-controlled workflow designed to ensure reproducible tumor growth, reliable therapeutic response assessment, and high-quality preclinical data output. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Line Authentication and Preparation: HCT-15 cells are authenticated via STR profiling and verified for mycoplasma contamination prior to expansion. Cells are cultured under standardized conditions (RPMI 1640 + 10--20% FBS, 37 degrees C, 5% CO2) and harvested at logarithmic growth phase for optimal viability upon implantation.
2. Recipient Mouse Selection and Acclimation: Immunocompromised mice (athymic nude or NOD-SCID, 6--8 weeks old) are acclimated for 5--7 days under specific-pathogen-free (SPF) conditions. Baseline body weights and health status are recorded to ensure suitability for the study.
3. Tumor Cell Implantation: For subcutaneous models, 1 x 10^6 to 5 x 10^6 HCT-15 cells suspended in a 1:1 mixture of serum-free medium and Matrigel are injected into the dorsal flank. For orthotopic models, cells are surgically implanted into the cecal wall or colonic submucosa under sterile conditions, enabling site-specific tumor growth.
4. Tumor Monitoring and Randomization: Tumor growth is monitored twice weekly using digital calipers (subcutaneous) or non-invasive imaging modalities such as bioluminescence or micro-CT (orthotopic). Upon reaching a palpable tumor volume of approximately 100--150 mm^3 (typically Day 13--18), mice are randomized into treatment and vehicle control groups.
5. Treatment Administration and In-Life Observations: Test compounds are administered via the designated route (oral gavage, intraperitoneal, or intravenous) according to the study protocol. Body weights, tumor dimensions, and clinical signs are recorded at defined intervals throughout the treatment period.
6. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and processed for histopathological examination (H&E staining), immunohistochemistry (IHC), and molecular analyses (RT-PCR, Western blot, RNA-seq). Blood and organ samples may be collected for toxicology and pharmacokinetic assessments.
7. Data Compilation and Reporting: All raw data, statistical analyses, and representative images are compiled into a comprehensive study report with tumor growth curves, survival plots, and histopathological summaries, delivered in a format ready for regulatory submission or publication.

Figure 2: Schematic workflow illustrating the derivation and construction of the HCT-15 Xenograft Model at Alfa Cytology.

Case Study-HCT-15 Xenograft Model Development

In a representative preclinical engagement, Alfa Cytology established HCT-15 cells into immunocompromised mice to evaluate the antitumor efficacy of a novel therapeutic candidate. Tumors established consistently within the expected timeframe, exhibiting histopathological features consistent with human colorectal adenocarcinoma. Treatment administration was well-tolerated, and longitudinal monitoring captured dose-dependent tumor growth inhibition relative to vehicle controls. Comprehensive endpoint analyses---including tumor weight assessment, H&E histopathology, and biomarker profiling---provided robust evidence of pharmacodynamic activity. Detailed quantitative results and full methodological parameters are available upon request under confidentiality agreements; please contact our scientific team to discuss data access and customized study design options.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your HCT-15 xenograft studies ensures access to validated preclinical models, rigorous quality standards, and dedicated scientific support throughout your research program.

• Verified Cell Line Integrity: Validated HCT-15 xenograft models with documented tumor take rates, growth kinetics, and histopathological fidelity to human colorectal adenocarcinoma.
• High Take Rates and Consistency: Flexible study designs supporting both subcutaneous and orthotopic implantation routes, with customizable treatment regimens and endpoint analyses.
• Integrated Imaging Capabilities: Comprehensive in-life monitoring capabilities including digital caliper measurements, bioluminescence imaging, and micro-CT for longitudinal tumor tracking.
• Comprehensive Analytical Support: Integrated endpoint analysis encompassing histopathology, immunohistochemistry, molecular profiling (RT-PCR, Western blot, RNA-seq), and biomarker quantification.
• Tailored Study Designs: Experienced scientific team with deep expertise in oncology preclinical modeling, ensuring protocol optimization, data integrity, and timely project delivery.
• Standardized Protocols: Strict quality control including STR authentication, mycoplasma screening, and SPF animal husbandry to guarantee reproducible and reliable experimental outcomes.

Contact Us

Ready to advance your colorectal cancer research with a validated HCT-15 xenograft model? Contact us today to discuss your project requirements, receive a customized study proposal, and learn how Alfa Cytology can accelerate your preclinical drug development pipeline. Our team is committed to delivering high-quality data and seamless project execution from study design through final reporting. Please reach out to us today via our inquiry form or email to learn more about our HCT-15 Xenograft Model services.

For research use only. Not intended for any clinical use.